Research in the Journal of the American Heart Association, based on the DATAFILE study involving 1,060 type 2 diabetes patients, found that metformin prescriptions were the only glucose-lowering medication to report a significant decline among those with a cardiovascular event, compared with those without CVE. Italian researchers found increases in insulin prescribing for those who were withdrawn from metformin after a CVE, compared with controls, while CV medication prescriptions substantially increased among both groups.
Study looks at changes in glucose-lowering medications after CV events
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.